957773-99-8

Upstream product

• 898538-71-1 4-(benzyloxy)-5-bromo-2-methylbenzaldehyde 
• 107-21-1 ethylene glycol 
• 875-59-2 4'-hydroxy-2'methylacetophenone 
• 957774-01-5 4-benzyloxy-5-bromo-2-methylbenzoic acid 
• 100-39-0 benzyl bromide 
• 608119-82-0 1-(4-(benzyloxy)-2-methylphenyl)ethanone 
• 101093-56-5 4-benzyloxy-2-methyl-benzaldehyde 
• 1000369-05-0 4-(benzyloxy)-5-bromo-N-methoxy-N-methylbenzamide 
• 957774-00-4 1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone 
• 1000369-04-9 4-(benzyloxy)-5-bromo-2-methylbenzoyl chloride 

Downstream Products

• 1000368-93-3 (1S)-1,5-anhydro-1-(2-hydroxy-5-[4-(4-{[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino}-4-oxobutyl)benzyl]-4-methylphenyl)-1-thio-D-glucitol 
• 1000368-94-4 (1S)-1,5-anhydro-1-{2-hydroxy-5-[4-(4-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino}-4-oxobutyl)benzyl]-4-methylphenyl}-1-thio-D-glucitol 
• 1000368-95-5 (1S)-1-[5-(4-{4-[(2-amino-1,1-dimethyl-2-oxoethyl)amino]-4-oxobutyl}benzyl)-2-hydroxy-4-methylphenyl]-1,5-anhydro-1-thio-D-glucitol 
• 957774-09-3 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[2-(benzyloxy)-4-methyl-5-[4-[2-(tritylamino)ethyl]benzyl]phenyl]-D-glucitol 
• 957774-10-6 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[5-[4-(2-aminoethyl)benzyl]-2-(benzyloxy)-4-methylphenyl]-D-glucitol 

Relevant academic research and scientific papers

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

The design and synthesis of a novel class of low-absorbable SGLT1 inhibitors are described. To achieve low absorption in the new series, we performed an optimization study based on a strategy to increase TPSA. Fortunately, the optimization of an aglycon m

1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

C-PHENYL GLYCITOL COMPOUND

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(RB)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(RB)RC, Formula (A) or Formula (B).